Foundry Healthcare 52-Week High Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1UNH | UNITEDHEALTH GROUP INC | Healthcare | $386.95B | 34.55% |
2CVS | CVS HEALTH CORP | Healthcare | $137.12B | 12.24% |
3HUM | HUMANA INC | Healthcare | $48.02B | 4.29% |
4RPRX | ROYALTY PHARMA PLC | Healthcare | $33.50B | 2.99% |
5CNC | CENTENE CORP | Healthcare | $32.81B | 2.93% |
6DXCM | DEXCOM INC | Healthcare | $29.58B | 2.64% |
7ILMN | ILLUMINA INC | Healthcare | $28.24B | 2.52% |
8INCY | INCYTE CORP | Healthcare | $23.42B | 2.09% |
9GH | GUARDANT HEALTH INC | Healthcare | $20.67B | 1.85% |
10VTRS | VIATRIS INC | Healthcare | $20.14B | 1.80% |
11NBIX | NEUROCRINE BIOSCIENCES INC | Healthcare | $17.18B | 1.53% |
12JAZZ | JAZZ PHARMACEUTICALS PLC | Healthcare | $15.53B | 1.39% |
13DVA | DAVITA INC | Healthcare | $15.21B | 1.36% |
14EXEL | EXELIXIS INC | Healthcare | $14.06B | 1.26% |
15BTSG | BRIGHTSPRING HEALTH SERVICES INC | Healthcare | $13.71B | 1.22% |
16TECH | BIO-TECHNE CORP | Healthcare | $11.29B | 1.01% |
17HSIC | HENRY SCHEIN INC | Healthcare | $10.00B | 0.89% |
18NUVL | NUVALENT INC | Healthcare | $9.79B | 0.87% |
19CORT | CORCEPT THERAPEUTICS INC | Healthcare | $9.72B | 0.87% |
20KYMR | KYMERA THERAPEUTICS INC | Healthcare | $9.52B | 0.85% |
21GKOS | GLAUKOS CORP | Healthcare | $9.21B | 0.82% |
22PTGX | PROTAGONIST THERAPEUTICS INC | Healthcare | $9.06B | 0.81% |
23CRNX | CRINETICS PHARMACEUTICALS INC | Healthcare | $8.84B | 0.79% |
24OSCR | OSCAR HEALTH INC | Healthcare | $8.77B | 0.78% |
25SYRE | SPYRE THERAPEUTICS INC | Healthcare | $8.70B | 0.78% |
26IMVT | IMMUNOVANT INC | Healthcare | $8.27B | 0.74% |
27PACS | PACS GROUP INC | Healthcare | $7.30B | 0.65% |
28MIRM | MIRUM PHARMACEUTICALS INC | Healthcare | $7.25B | 0.65% |
29LQDA | LIQUIDIA CORP | Healthcare | $7.11B | 0.63% |
30CHE | CHEMED CORP | Healthcare | $6.77B | 0.60% |
31HNGE | HINGE HEALTH INC | Healthcare | $6.74B | 0.60% |
32XENE | XENON PHARMACEUTICALS INC | Healthcare | $6.60B | 0.59% |
33CGON | CG ONCOLOGY INC | Healthcare | $6.34B | 0.57% |
34ERAS | ERASCA INC | Healthcare | $5.96B | 0.53% |
35TFX | TELEFLEX INC | Healthcare | $5.96B | 0.53% |
36DNTH | DIANTHUS THERAPEUTICS INC | Healthcare | $5.77B | 0.52% |
37TXG | 10X GENOMICS INC | Healthcare | $5.55B | 0.50% |
38KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | Healthcare | $4.92B | 0.44% |
39VCYT | VERACYTE INC | Healthcare | $4.72B | 0.42% |
40LFST | LIFESTANCE HEALTH GROUP INC | Healthcare | $4.49B | 0.40% |
41CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $4.04B | 0.36% |
42ICUI | ICU MEDICAL INC | Healthcare | $3.94B | 0.35% |
43DYN | DYNE THERAPEUTICS INC | Healthcare | $3.92B | 0.35% |
44CPRX | CATALYST PHARMACEUTICALS INC | Healthcare | $3.85B | 0.34% |
45RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.81B | 0.34% |
46NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.56B | 0.32% |
47PRVA | PRIVIA HEALTH GROUP INC | Healthcare | $3.39B | 0.30% |
48ELVN | ENLIVEN THERAPEUTICS INC | Healthcare | $3.24B | 0.29% |
49MBX | MBX BIOSCIENCES INC | Healthcare | $2.99B | 0.27% |
50ESTA | ESTABLISHMENT LABS HOLDINGS INC | Healthcare | $2.72B | 0.24% |
51TRVI | TREVI THERAPEUTICS INC | Healthcare | $2.71B | 0.24% |
52PGNY | PROGYNY INC | Healthcare | $2.50B | 0.22% |
53VCEL | VERICEL CORP | Healthcare | $2.38B | 0.21% |
54PVLA | PALVELLA THERAPEUTICS INC | Healthcare | $2.26B | 0.20% |
55IOVA | IOVANCE BIOTHERAPEUTICS INC | Healthcare | $2.23B | 0.20% |
56SION | SIONNA THERAPEUTICS INC | Healthcare | $2.23B | 0.20% |
57MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.15B | 0.19% |
58GLUE | MONTE ROSA THERAPEUTICS INC | Healthcare | $2.07B | 0.19% |
59CDNA | CAREDX INC | Healthcare | $2.05B | 0.18% |
60RAPP | RAPPORT THERAPEUTICS INC | Healthcare | $2.04B | 0.18% |
61PLSE | PULSE BIOSCIENCES INC | Healthcare | $1.98B | 0.18% |
62URGN | UROGEN PHARMA LTD | Healthcare | $1.96B | 0.18% |
63DMRA | DAMORA THERAPEUTICS INC | Healthcare | $1.94B | 0.17% |
64SNDA | SONIDA SENIOR LIVING INC | Healthcare | $1.93B | 0.17% |
65NEO | NEOGENOMICS INC | Healthcare | $1.90B | 0.17% |
66MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.17% |
67HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.74B | 0.16% |
68MPLT | MAPLIGHT THERAPEUTICS INC | Healthcare | $1.72B | 0.15% |
69TDOC | TELADOC HEALTH INC | Healthcare | $1.70B | 0.15% |
70FTRE | FORTREA HOLDINGS INC | Healthcare | $1.68B | 0.15% |
71PSNL | PERSONALIS INC | Healthcare | $1.61B | 0.14% |
72IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.50B | 0.13% |
73PNTG | PENNANT GROUP INC | Healthcare | $1.46B | 0.13% |
74XNCR | XENCOR INC | Healthcare | $1.30B | 0.12% |
75DRTS | ALPHA TAU MEDICAL LTD | Healthcare | $1.19B | 0.11% |
76ETON | ETON PHARMACEUTICALS INC | Healthcare | $1.16B | 0.10% |
77BVS | BIOVENTUS INC | Healthcare | $1.01B | 0.09% |
78FBRX | FORTE BIOSCIENCES INC | Healthcare | $1.00B | 0.09% |
79TALK | TALKSPACE INC | Healthcare | $873M | 0.08% |
80HSTM | HEALTHSTREAM INC | Healthcare | $832M | 0.07% |
81MNPR | MONOPAR THERAPEUTICS | Healthcare | $744M | 0.07% |
82NGNE | NEUROGENE INC | Healthcare | $590M | 0.05% |
83STTK | SHATTUCK LABS INC | Healthcare | $577M | 0.05% |
84NVCT | NUVECTIS PHARMA INC | Healthcare | $508M | 0.05% |
85NRC | NRC HEALTH | Healthcare | $491M | 0.04% |
86VMD | VIEMED HEALTHCARE INC | Healthcare | $466M | 0.04% |
87SI | SHOULDER INNOVATIONS INC | Healthcare | $448M | 0.04% |
88DCTH | DELCATH SYSTEMS INC | Healthcare | $442M | 0.04% |
89PBYI | PUMA BIOTECHNOLOGY INC | Healthcare | $434M | 0.04% |
90TBRG | TRUBRIDGE INC | Healthcare | $394M | 0.04% |
91ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.03% |
92TTRX | TURN THERAPEUTICS INC | Healthcare | $272M | 0.02% |
93QTTB | Q32 BIO INC | Healthcare | $255M | 0.02% |
94UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $222M | 0.02% |
95FOCL | FOCAL INC | Healthcare | $204M | 0.02% |
96CPIX | CUMBERLAND PHARMACEUTICALS INC | Healthcare | $103M | 0.01% |
97ICCC | IMMUCELL CORP | Healthcare | $101M | 0.01% |
98RLYB | RALLYBIO CORP | Healthcare | $87M | 0.01% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $1.12T. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 96% toward Large, 62% toward Growth. +6% unclassified (10 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 98 names now. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Required>= 75.0%Actual63.2%Margin-11.8%No more than 25% of total assets may be invested in the securities of any one issuer.
Required<= 25.0%Actual34.6%Margin-9.6%Days required to liquidate the largest position at 20% of one day's dollar volume.
Required<= 7.0 daysActualunboundedMargin—
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 98 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 38.9% | 12.2% |
| 3 yearsp.a. | 4.5% | -6.1% |
| 5 yearsp.a. | 3.4% | -4.0% |
| 10 yearsp.a. | 7.3% | -6.7% |
| Since inceptionp.a. | 7.0% | -11.5% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 16.7% | 26.6% |
| 2025 | 12.7% | -8.6% |
| 2024 | -7.2% | -16.5% |
| 2023 | -5.6% | -35.5% |
| 2022 | -1.5% | 10.5% |
| 2021 | 6.0% | -0.8% |
| 2020 | 16.6% | -32.8% |
| 2019 | 17.1% | -7.1% |
| 2018 | 14.3% | 30.0% |
| 2017 | 19.5% | 6.4% |
| 2016 | -1.1% | 19.0% |
| 2015 | 0.4% | -4.3% |
| 2014 | 22.8% | -19.3% |
| 2013 | 38.1% | -4.4% |
| 2012 | 17.8% | -22.0% |
| 2011 | 12.7% | 19.7% |
| 2010 | 2.2% | -15.6% |
| 2009 | 9.3% | -42.4% |
| 2008 | -18.0% | -25.6% |
| 2007 | 17.4% | 16.4% |
| 2006 | 4.9% | -7.3% |
| 2005 | 14.0% | 18.7% |
| 2004 | 6.3% | -16.6% |
| 2003 | 21.4% | -13.5% |
| 2002 | -18.6% | -3.4% |
| 2001 | -15.7% | -50.3% |
| 2000 | 14.5% | -54.8% |
| 1999 | -0.1% | -2.5% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare 52-Week High Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a 52-Week High signal and holds the top quintile with the highest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.